Editas Medicine, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Editas Medicine (EDIT) is advancing EDIT-401, a CRISPR therapy aiming for up to 90% LDL cholesterol reduction. First patient dosing is expected this year, with safety data in Q1 2027 and top-line results in 2027. The company has a strong cash position to support these milestones, according to its Cantor Fitzgerald conference presentation.
Editas Medicine (NASDAQ:EDIT) plans to start a Phase 1 trial for its CRISPR-based cholesterol therapy, EDIT-401, in Australia this year. The trial aims to treat patients with heterozygous familial hypercholesterolemia. Preclinical data suggests a 15% allele edit could significantly lower cholesterol. The company has $212 million in cash and expects its runway to extend into mid-2028.
Editas Medicine, Inc. (EDIT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Editas Medicine Announces Second Quarter 2026 Results and Business Updates EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoprotei
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning EDIT (Editas Medicine, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent EDIT coverage spans technology, insider activity and earnings.
In the last 30 days, EDIT insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($19K). The most active reporter was Parison Amy, SVP, Chief Financial Officer, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Clinical development timeline and efficacy target for EDIT-401 are the core catalysts for EDIT’s risk/reward into upcoming safety and topline readouts.
Positive trial initiation news may lift EDIT on short-term sentiment.
Near-term catalysts are the Australia CTN submission and the next EDIT-401 data update, supported by an extended cash runway into 2H 2028 after financing.
Routine shareholder-meeting outcomes; no new operational or financial guidance disclosed.
Insider selling is a modest, mostly non-fundamental signal given the stated pre-arranged 10b5-1 plan; near-term impact is likely limited.
AlphAI scores every news story that mentions EDIT with an AI model for sentiment and relevance, and aggregates insider trades from Editas Medicine, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Editas Medicine (EDIT) is advancing EDIT-401, a CRISPR therapy aiming for up to 90% LDL cholesterol reduction. First patient dosing is expected this year, with safety data in Q1 2027 and top-line results in 2027. The company has a strong cash position to support these milestones, according to its Cantor Fitzgerald conference presentation.
1 min readEditas Medicine (NASDAQ:EDIT) plans to start a Phase 1 trial for its CRISPR-based cholesterol therapy, EDIT-401, in Australia this year. The trial aims to treat patients with heterozygous familial hypercholesterolemia. Preclinical data suggests a 15% allele edit could significantly lower cholesterol. The company has $212 million in cash and expects its runway to extend into mid-2028.
2 min readEditas Medicine, Inc. (EDIT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Editas Medicine Announces Second Quarter 2026 Results and Business Updates EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoprotei
4 min readEditas Medicine, Inc. (EDIT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. edit-20260617 0001650664 FALSE 0001650664 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________________________________________________________________ FORM 8-K _____________________________________________
2 min readO'Neill Gilmore Neil (CEO) sold 15,380 shares of Editas Medicine, Inc. (EDIT) at $2.70 on 2026-06-03 under a Rule 10b5-1 trading plan.
1 min readBurkly Linda (EVP, CHIEF SCIENTIFIC OFFICER) sold 731 shares of Editas Medicine, Inc. (EDIT) at $2.70 on 2026-06-03 under a Rule 10b5-1 trading plan.
1 min readBiotech stocks rose on varied catalysts. Q32 Bio (QTTB) jumped 85% after a $55M private placement at $8.00/share; topline SIGNAL-AA Phase 2a Part B data are expected mid-2026. Soligenix (SNGX) gained 69% as it evaluates ThermoVax for Bundibugyo Ebola. Guardant (GH) rose 6% after ACS added its Shield blood test to updated colorectal screening guidelines; Q1 revenue was $301.7M (+48%).
6 min readEditas Medicine (NASDAQ:EDIT) saw unusually heavy options activity Wednesday, with investors buying 2,160 call options, up about 245% versus average daily volume. Shares rose to $3.77 midday. The article also cites May 5 earnings: EPS of -$0.26 vs -$0.30 expected, revenue $2.83M vs $6.37M, and notes multiple analyst price targets.
4 min readEditas Medicine reported preclinical results for EDIT-401, an in vivo gene-editing system targeting the LDLR gene to lower LDL-C. In non-human primates, it showed about a 90% mean reduction in LDL-C and roughly 90% reductions in Lp(a) and ApoB, with correlated biomarker changes. GLP toxicology is ongoing with interim tolerability and no liver histopathology. The company plans an HeFH patient trial later this year and an IND filing after a successful FDA pre-IND meeting; shares fell on the news.
4 min readEditas Medicine Inc. (EDIT) reported a first-quarter loss of $25 million, or 26 cents per share, which exceeded Wall Street expectations. However, the genome editing company's revenue of $2.8 million for the period fell short of analysts' forecasts. This financial snapshot highlights Editas's mixed performance in its latest earnings report.
2 min read
